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AbstrACt
Objectives Electronic patient self-Reporting of Adverse-
events: Patient Information and aDvice (eRAPID) is 
an online system developed to support patient care 
during cancer treatment by improving the detection and 
management of treatment-related symptoms. Patients 
can complete symptom reports from home and receive 
severity-based self-management advice, including 
notifications to contact the hospital for severe symptoms. 
Patient data are available in electronic records for staff 
to review. Prior to the commencement of a randomised 
controlled trial (RCT), field testing of the intervention 
was undertaken to troubleshoot practical issues with 
intervention integration in clinical practice.
Design Observational clinical field testing.
setting Medical oncology breast service in a UK cancer 
centre.
Participants 12 patients receiving chemotherapy for early 
breast cancer and 10 health professionals (oncologists and 
specialist nurses).
Intervention Patients were asked to use the eRAPID 
intervention and complete weekly online symptom 
reports during four cycles of chemotherapy. Clinical staff 
were invited to access and use patient data in clinical 
assessments.
Analysis Descriptive data on the frequency of online 
symptom report completion and severe symptom 
notifications were collated. Verbal and written feedback 
was collected from patients and staff and semistructured 
interviews were conducted to explore patient experiences. 
Interviews were transcribed and analysed thematically.
results The testing ran from January 2014 to March 
2014. Feedback from patients and staff was largely 
positive. Patients described eRAPID as ‘reassuring’ and 
‘comforting’ and valued the tailored management advice. 
Several changes were made to refine eRAPID. In particular, 
improvement of the clinical notification, patient reminder 
systems and changes to patient and staff training.
Conclusions The field testing generated valuable results 
used to guide refinement of eRAPID prior to formal 
intervention evaluation. Feedback indicated that eRAPID 
has the potential to improve patients’ self-efficacy, 
knowledge and confidence with managing symptoms 
during treatment. A large-scale RCT is underway with data 
collection due to finish in October 2018.
IntrODuCtIOn   
Systemic cancer treatment is associated with 
a range of side effects which can negatively 
impact patients’ quality of life (QOL) and 
become life threatening.1 As patients typically 
receive chemotherapy in outpatient settings, 
they are largely required to self-monitor 
symptoms at home. Patients can lack confi-
dence in making decisions between obtaining 
clinical support or self-managing2 and can 
delay seeking medical advice,3 4 heightening 
the risk of symptom escalation and hospital 
admissions.5 Conversely subgroups of patients 
may routinely contact the hospital for reassur-
ance in relation to mild side effects.2 
There is growing evidence that the utilisa-
tion of patient-reported outcome measures 
during cancer treatment can aid the timely 
identification of physical and psychosocial 
needs, facilitate patient–doctor communica-
tion and assist decision-making.6–10 There has 
been a drive to develop electronic systems to 
allow remote real-time patient monitoring 
during cancer.11–13 Positive patient benefit 
(including QOL and survival) was recently 
strengths and limitations of this study
 ► The strengths of this field usability testing include 
the mixed methodological approach (combining 
qualitative and observational data) and the involve-
ment of both patient and staff representatives.
 ► This type of embedded clinical testing is vital for de-
termining how new interventions work in practice.
 ► The results are limited by the focus on one cancer 
group.
 ► An ongoing randomised controlled trial will assess 
the impact of the Electronic patient self-Reporting of 
Adverse-events: Patient Information and aDvice on-
line intervention on patients with cancer, oncology 
staff and health services.
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reported in a US trial of an online system for metastatic 
cancer treatment.14
We developed an online intervention for supporting 
patient care during and after cancer treatment. Elec-
tronic patient self-Reporting of Adverse-events: Patient 
Information and aDvice (eRAPID)15 is web based and 
accessible from home or mobile device, for patients to 
complete symptom reports and receive severity-based 
advice. Recommendations for self-management are 
provided for milder symptoms and advice for when to 
contact the hospital for severe issues. A graphing feature 
allows patients to review personal symptom data over time. 
The system includes a facility to notify healthcare teams 
via email when a severe symptom is reported. Patient-re-
ported data are transferred in real time to be accessed 
by health professionals through the hospital electronic 
patient records (EPRs) for use in routine consultations 
and assessments.
Following recommended usability principles of agile 
development,16 we involved staff and patient representa-
tives throughout the eRAPID developmental processes, 
using an iterative design approach.17 Results from the 
technical usability testing are reported elsewhere.15 18 
Here, we describe the field usability testing phase where 
staff and patients used eRAPID in a real-life clinical 
setting to troubleshoot practical issues not identified 
by standard usability testing19 20 and allow streamlining 
of eRAPID clinical integration prior to commencing a 
formal randomised controlled trial (RCT).21
Aims
For patients, the aims were to ensure:
 ► System training was sufficient and feasible.
 ► Routine (weekly) online symptom report completions 
were acceptable.
 ► Self-management advice and severe symptom notifica-
tions were useful and appropriate.
For clinical staff, the aims were to ensure:
 ► System training provided was sufficient and feasible.
 ► Symptom report data were easy to access in the EPR 
and comprehensible.
 ► Severe symptom notifications were correctly activated.
In addition, we wanted to assess the overall reliability of 
the Information Technology (IT) underpinning eRAPID.
MethODs
Patient and public involvement
The eRAPID research programme has involved patient 
representation and collaboration at each stage from 
conception, funding application (involvement of a 
patient and public involvement coapplicant) and 
research delivery (membership on project management 
and steering committees). The eRAPID intervention was 
designed with substantial input from patient representa-
tives from our dedicated Research Advisory Group (RAG). 
RAG members contributed to initial usability testing of 
the patient facing aspects of the IT system and advised 
on the content of the self-management advice.22 This 
paper describes the subsequent phase of usability work, 
where the intervention was taken for the first time for 
field testing in a clinical context with patients receiving 
chemotherapy and their associated care teams.
Clinical setting
The field usability testing was conducted in the breast 
medical oncology service at St James’s University Hospital, 
Leeds, UK. The Leeds Teaching Hospitals NHS Trust 
Research & Innovation Department approved the exer-
cise as a service evaluation. Procedures were undertaken 
in line with Data Protection23 and Good Clinical Practice 
guidelines.24
Patient eligibility and identification
Patient eligibility criteria were (1) early breast cancer 
diagnosis, (2) starting at least four planned cycles of 
adjuvant/neoadjuvant systemic treatment, (3) internet 
access at home and (4) proficient English (to understand 
symptom assessments and self-management advice). 
Patients were identified by clinical staff and eRAPID was 
introduced by an oncologist or clinical nurse specialist 
(CNS). Interested patients were given an informa-
tion sheet and passed to the eRAPID team for further 
information.
erAPID demonstration and training
The eRAPID system is described in detail elsewhere.15 See 
figure 1 for a system overview.
Patient symptom report and training
Participating patients received written information to 
take home and the researcher arranged to meet them 
at their first chemotherapy visit, where unique eRAPID 
login details were provided alongside a user manual. 
Patients were asked to complete the online eRAPID 
symptom report weekly (or more frequently if preferred) 
throughout four chemotherapy cycles (approximately 
12 weeks). The online symptom report contained items 
from the locally devised patient-reported adverse event18 
item bank based on the Common Terminology Criteria 
for Adverse Events grading system.25 Working in collabo-
ration with the breast oncology staff, 12 core items were 
chosen for the main report (including pain, fatigue, phys-
ical activity, bowel function, sleep, temperature, chill, 
sore mouth and appetite). There was also the option for 
patients to add details on additional issues via a drop-
down list of further symptoms and a free text option.
Clinical staff training
The breast CNSs were shown how to access eRAPID 
symptom report data in the EPR and given a one-page 
instruction sheet. They were also added to a mailing list to 
receive severe symptom notifications and encouraged to 
contact patients where feasible. Oncologists were trained 
on a needs-driven basis, receiving a demonstration and 
a one-page instruction sheet immediately prior to an 
eRAPID patient consultation.
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evaluation methods
Patient evaluation
Information on system acceptability and general feed-
back were collected through a number of methods:
 ► The number of full symptom report completions and 
adherence to the weekly completion schedule.
 ► Patients were provided with email and telephone 
contact details for the research team and a researcher 
met with the patient at their routine hospital appoint-
ments to check progress. The content of these commu-
nications was documented and collated.
 ► Patients were asked to complete brief feedback in the 
user manual covering ease of system use and general 
comments or recommendations.
 ► Patients were interviewed at the end of the testing. 
Semistructured interviews explored views on the tech-
nical practicalities, relevance/impact of the self-man-
agement advice and staff use of the reports and impact 
on medical management.
Clinical staff evaluation
Testing of the eRAPID system from the professionals’ 
perspective involved:
 ► Completion of brief written feedback forms to record 
use of the eRAPID data and any impact on the 
consultation.
 ► Direct observation of a subset of consultations where 
eRAPID information was available for staff. The 
researcher sat in the room and took field notes to 
describe how staff used eRAPID data.
 ► Details of any severe symptom notifications sent to 
staff during the 12-week assessment were documented 
along with any action taken.
 ► Ad hoc verbal feedback from staff was also docu-
mented by researchers throughout the 12-week 
assessment.
Evaluating the reliability of IT processes
Any IT issues reported by researchers, patients or staff 
during the assessment period were logged along with the 
action taken.
Iterative refinement of erAPID
Throughout testing the research team collated feed-
back and identified issues were regularly fed back to 
the eRAPID project management team (consisting of 
Figure 1 Overview of eRAPID system illustrating the flow of data from inside and outside the hospital. EPR, electronic patient 
record; eRAPID, Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice; NHS, National Health 
Service.  
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oncologists, nurses, health informatics experts, patient 
representatives and researchers). The team decided how 
issues should be resolved and where eRAPID could be 
improved for the future RCT. A full report was prepared 
at the end of the testing, documenting all identified issues 
and actions taken.
Analysis
Patient and clinical staff evaluation
Descriptive accounts of the number of completed 
eRAPID symptoms reports were created along with the 
frequency of severe symptom notifications. Verbal feed-
back, comments from the user manuals, written feedback 
and notes taken during clinic observations were assimi-
lated and categorised into themes.
Interviews were audio recorded, transcribed verbatim 
and managed in NVivo V.9. Initially a pragmatic approach 
was employed where any important issues raised in inter-
views were taken to the project management team to 
guide any immediate action. Interview data were subse-
quently fully coded and analysed thematically.26
results
Participants
Patients
Testing took place between January and March 2014 with 
12 patients (mean age=47.5 years, SD=10.3, range 33–73 
years) (see figure 2).
Clinical staff
Ten members of the breast care team participated 
including two adjuvant breast CNSs and eight doctors (four 
senior oncology consultants, four oncology trainees). 
Patients typically saw a CNS routinely throughout the 
12 weeks and had one appointment with an oncologist 
before their third chemotherapy cycle.
evaluation of erAPID
Figure 3 shows a summary of data collected from staff and 
patients.
Compliance with weekly symptom reports
Over the testing period 104 full symptom reports were 
completed, 42% (5/12) of patients completed the report 
11–13 times, 33% (4/12) completed 7–9 times and 25% 
(3/12) completed 4–6 times. Average adherence to 
weekly completion (ie, actual/expected completions per 
patient) was 63% (range 33%–92%).
Interviews revealed the most common reason for 
non-completion of the symptom report was simply forget-
ting. Most patients were in favour of a text or email 
reminder (n=8). Patients reported not completing the 
report when very unwell, stating it was not a priority. 
Others were unsure how often they should be completing. 
Feedback from the user manuals and interviews demon-
strated that all the patients found eRAPID easy to use and 
did not report problems locating, logging in or using the 
system. A couple of minor suggestions were made for 
improvement, which were subsequently addressed (see 
table 1).
severe symptom notifications
Eight severe symptom notifications were activated, seven 
were not appropriate due to the framing of the symptom 
items which asked patients to report symptom experience 
within the last 7 days. This led to occasions where severe 
symptoms were being retrospectively reported with noti-
fications activated for resolved problems. One patient 
found this experience alarming and stopped using 
eRAPID as a consequence.
It brought the alert up, and the hospital rang and 
thought I might possibly need an admission, I must 
admit that scared me a little bit…I said well no ac-
tually, these symptoms were a few days ago and now 
I’m absolutely fine… it were fantastic that they rang 
so quickly and I think it’s a great system for that, but 
I just thought oh no, I don’t want to go to hospital 
(Female, 44)
Figure 2 Overview of patients approached and participating 
in the eRAPID field usability testing network. eRAPID, 
Electronic patient self-Reporting of Adverse-events: Patient 
Information and aDvice.
Figure 3 Summary of evaluation data collected from 
patients and staff. CNSs, clinical nurse specialists.
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Table 1 Summary of identified issues and actions taken to refine the intervention following field usability testing
Theme/area Issue identified Action taken
Procedures for remote access and symptom report completion
Graphs Patients have the option to report ‘other’ free text 
symptoms at the end of the symptom report. However, 
the graphs displaying these symptoms looked odd when 
symptoms were not reported regularly.
Decision made to remove these graphs as they 
did not add much value and were confusing for 
patients.
The headings on the graphs (symptom names) did not 
always correspond with those on the questionnaire
The research team to ensure labelling kept 
consistent.
System usability Patients have access to a link at the end of their 
symptom report (‘email your feedback’) to email their self-
management advice to themselves. However, patients 
expected this link to enable them to provide the research 
team with feedback on the eRAPID system.
Wording changed this from ‘email your 
feedback’ to ‘send this information to your email 
address’.
Symptom report Patients wanted to provide additional information about 
symptoms, such as when they experienced them or the 
type of pain they had.
Two changes were implemented:
1. If a patient reported ‘severe’ symptoms, 
they were then asked a branching question 
to determine if it was a current problem or a 
problem that had now resolved.
2. A free text box was added to the pain 
question so that patients could provide 
information about the site of pain.
One patient felt there were too many questions and 
that they were not all relevant. She suggested that we 
should add an option for patients to say ‘I feel fine’ or ‘My 
symptoms haven’t changed’.
After discussion with the research and wider 
project management teams, we decided against 
implementing this, as it would not be as useful 
for clinical practice.
Practicalities of 
completion
The most common reasons for not completing were 
forgetting, feeling too unwell, not experiencing symptoms 
or not realising they should complete weekly.
Implementation of an automated reminder 
system to send patients weekly reminders via 
text or email. In patient training, researchers will 
emphasise the importance of completing weekly, 
even if they are not experiencing symptoms.
Self-management 
advice
One patient queried what to do if symptoms are not 
improving when you are following the advice and 
suggested we encourage patients to talk to their clinical 
team if this is the case.
This advice was added to the self-management 
feedback
Suggestion to add some additional links to well used 
external websites to make it a more complete resource.
After discussion, it was decided not to add links 
for external websites, as we would not be able 
to ensure that they were always up to date, and 
patients are directed to these sites by the clinical 
team.
Add specific advice on achy veins and hot flushes. Self-management advice was added for these 
issues.
Notifications Severe symptom notifications were being triggered for 
patients reporting retrospective problems (due to item 
framing asking patients to report symptom experience 
within the last 7 days).
A branching question was added to ask patients 
‘Is this a current problem?’ if a severe symptom 
was reported. A notification would then be sent 
only if patients answered yes to this question.
Several notifications were triggered for physical activity 
when patients felt it was not warranted.
Following discussion with clinical staff the 
threshold was increased for this item. In addition 
to the branching question regarding whether 
the symptom is current, a second branching 
question was added for this symptom to ask if 
patients had help at home.
Staff notifications
Notifications Clinical staff suggested that it may be helpful to have 
the facility to comment on a notification in the EPR to let 
other staff know it had been actioned (eg, by phoning the 
patient). 
This facility was added so staff could mark 
a notification as ‘responded’ and make an 
annotation.
Continued
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In addition, patients sometimes felt that notifications 
were not warranted for the symptom severity experi-
enced, in particular, those for low physical activity:
It more or less panicked you a bit and said contact 
the hospital immediately… Because I still think I’d 
classed it correctly. It didn’t warrant an ambulance at 
the door or anything like that. (Female, 47)
However, the notifications worked well for the one 
patient who experienced an injection site reaction for 
several days. On completing the symptom report, she 
followed the advice to contact the hospital:
I wasn’t sure whether I should, so that advice was 
good. It will be good for people like that who are bor-
derline. (Female, 73)
Following testing, the symptom report was refined 
to accommodate the notification issues identified (see 
table 1).
thematic analysis of patient interviews
The following themes were identified:
Increasing knowledge and confidence
The self-management advice empowered patients by 
providing information and support to personally manage 
symptoms. Patients felt confident doing this, in the knowl-
edge that the system provided a ‘safety net’:
It’s like a life line when you feel isolated when you’re 
at home and feeling poorly…you can have a lot of 
questions or problems regarding your illness and 
with one click they can be answered and absorbed 
within minutes. (Female, 49).
I would recommend it to anyone. It’s like a safety net 
for you and gives you the help to keep on going on 
through your treatment (Female, 73)
I think it does make you feel a bit happier—if you 
read something on there that says well, you will feel 
like this but you can do this, this and this… you’re 
happy with that (Female, 50)
Supporting decision-making
Patients felt that using eRAPID helped reduce their worry 
by aiding decision-making helping them feel more knowl-
edgeable about when to self-manage and when to contact 
the hospital:
I’m a bit of a worrier and I think ‘shall, shan’t I, am I 
over-reacting?’ But I think that then would confirm to 
people that yeah, you should really ring the hospital 
so… it’s just like a little bit of extra home support isn’t 
it really? (Female, 33)
Coping strategy
Some patients found the symptom graphing feature 
useful for understanding patterns and this could be both 
reassuring and motivating.
For me personally, I just think I can’t do this anymore, 
I don’t like this, this is awful, and I find that I’m very 
disheartened and I can’t see an end to it……But then 
when you look at the graphs, you can think, but I did 
get better…and my mouth has got better, and my di-
arrhoea has stopped and… you can see that there is 
a pattern and that it will get better. It makes me feel 
better. (Female, 60)
staff evaluation
Notifications for severe symptoms
Clinical staff agreed that notifications for retrospectively 
reported severe symptoms were not relevant and that 
some of the notifications sent for low physical activity 
were unwarranted. When this issue was identified, email 
Theme/area Issue identified Action taken
Accessibility and interpretability of eRAPID symptom report data for staff
User interface Several clinical staff members commented that it would 
be very useful for them to be able to see chemotherapy 
cycles on patients’ symptom report graphs. 
Red triangle added on the graphs to denote date 
of chemotherapy cycle delivery.
Where a patient score was 0, it looked like the item had 
not been completed. 
This was only an issue for the patients’ first 
completion (which showed as a bar graph, 
rather than a line graph), these were amended 
so that it was clearer when symptoms were 
scored as 0.
The line graphs depicting patient symptom reports had 
a red line to show where symptoms became severe and 
a notification would be triggered. This was confusing for 
staff. 
Red line showing severity levels was removed.
Staff found the symptom reports less useful when 
patients were not completing regularly. Patients were not 
always aware if staff were using their symptom reports or 
not. 
In future training staff were asked to encourage 
patients to complete regularly and explicitly refer 
to and use the results in consultations.
Table 1 Continued 
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notifications were redirected to the eRAPID research 
nurse for the remainder of the field testing, who liaised 
with patients and clinical staff where needed.
eRAPID patient symptom report data
The staff feedback forms indicated that symptom 
report data were easy to access and interpret and useful 
for identifying issues/problems for discussion (n=6), 
confirming knowledge of the patient’s problems, (n=5), 
providing additional information (n=5) and contributing 
to management (n=3). Several staff commented that 
it would assist interpretation of symptom reports if the 
EPR graphical displays included dates of chemotherapy 
delivery. In addition, staff commented that symptom 
information was most useful where patients had routinely 
provided reports throughout treatment.
The consultation observations confirmed that staff 
could easily access the symptom reports in the EPR but 
there were variations in utilisation. Some staff viewed 
the data but did not explicitly mention this to patients 
whereas others used it as a point of reference to guide the 
consultation and made this clear to patients.
reliability of It processes
The IT processes were largely stable. The notification 
system was reliable, with the patient and staff severe 
symptom notifications activated as expected. The patient 
symptom reports became temporarily unavailable to staff 
at one point. The problem was reported to the team and 
was resolved by the IT manager that day.
refinement of erAPID intervention and processes for 
integration
Following feedback from staff and patients, several 
improvements were made to streamline the integration 
of eRAPID into the clinical setting (table 1).
DIsCussIOn
The aim of this field usability testing was to observe end 
users (staff and patients) use of eRAPID in a real-life 
clinical setting in order to troubleshoot practical issues 
which may not be identified through standard usability 
testing.19 20 Feedback received from both patients and 
staff was positive and demonstrated the system was well 
received but also led to important modifications and 
improvements. The process allowed streamlining of inter-
vention integration into clinical practice prior to formal 
evaluation.21
The majority of the notifications triggered for severe 
symptoms were for resolved symptoms patients reported 
retrospectively. This led to two key adjustments to the 
system prior to the RCT to avoid ‘false’ notifications and 
limit unnecessary patient worry and clinical burden. 
First, we added a branching question to allow patients 
reporting symptoms to provide further clarification on 
whether the symptom was ongoing or had been resolved. 
Second, the physical activity severity threshold was raised 
as both patients and clinical staff felt the original setting 
was too low. This was off-putting to patients and encour-
aging unwarranted hospital contact. For additional safe-
guarding, a further branching question was also added to 
this item to determine if patients reporting problems had 
help/support at home and assist with the identification of 
more vulnerable individuals.
Patients found eRAPID easy to use but many forgot to 
routinely complete the weekly report. As a consequence, 
the proposed text message/email reminder system was 
subsequently established. Patients reported valuing the 
self-management advice, particularly specific advice 
about when to contact the hospital and several patients 
described the system as ‘reassuring’ and a ‘safety net’. The 
testing highlighted the reciprocal relationship between 
patient and staff engagement in the system. Although 
staff felt the symptom reports were most valuable when 
routinely completed by patients, they did not always 
explicitly mention using the data in consultations. Moving 
forward in the RCT, we conducted a series of one-to-one 
and group training sessions with relevant staff involved 
in chemotherapy delivery and assessments (oncologists, 
CNSs, preassessment nursing teams). The sessions have 
included didactic elements (describing the eRAPID 
developmental work and the evidence supporting the 
use of using patient-reported data in clinical practice) 
and practical demonstrations of how to access patient-re-
ported data. More recently an online training package 
was also created (accessible via a hyperlink in the EPR) 
which allows staff to view information as required. 
This online resource includes practical refreshers on 
accessing patient symptom reports along with interactive 
case studies that demonstrate how the data can be inter-
preted and used. There is emphasis within all the training 
formats on the importance of making overt reference to 
symptom reports with patients in clinical encounters to 
endorse the value of patient-reported data and encourage 
ongoing completions.
The interviews revealed the intervention could have the 
potential to increase patient self-efficacy and engagement 
with the management of their care. A recent systematic 
review has demonstrated the importance of self-efficacy 
in managing pain, symptoms and function in patients 
with cancer.27 In addition, high levels of patient activation 
(how engaged a patient is in their own healthcare) are 
associated with an array of improved health behaviours 
and health outcomes28–30 while lower levels of activation 
are associated with higher use of hospital resources.31
In the large-scale eRAPID RCT, the main outcomes 
focus on patient QOL and clinical process data (contacts 
with the hospital, emergency admissions) but we will also 
explore psychological variables that may help us more 
fully understand how patients can benefit from eRAPID.21 
Specifically, we will explore the relationship between 
patients’ self-efficacy, patient activation32 and utilisa-
tion of the eRAPID system, self-management advice and 
symptom graphs. The WebChoice system in Norway has 
demonstrated that enabling patients to self-manage can 
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be more beneficial for patients than symptom reporting 
alone.33
This field usability testing had some limitations. We only 
had the capacity (in terms of both staffing resources and 
time restrictions) to evaluate the system with patients with 
early breast cancer. These patient groups are relatively 
young compared with other adult cancer groups and are 
more likely to be digitally agile. However, internet access 
continues to increase34 and previous work has indicated 
that electronic systems are acceptable in other cancer 
groups.11 15 35–37 The RCT evaluates eRAPID in a broader 
population, specifically patients receiving chemotherapy 
for breast, gynaecology or colorectal cancer have been 
recruited from both adjuvant and metastatic treatment 
pathways.21
In summary, the field testing helped endorse the prac-
tical potential of eRAPID for supporting patient care but 
importantly uncovered issues which would not have been 
identified with standard usability testing alone. This was 
an invaluable exercise prior to the commencement of 
the ongoing RCT (data collection due to be completed 
in October 2018) which will evaluate the potential bene-
fits of eRAPID for patients, staff and the National Health 
Service.
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